2024
Adolescent Residential Addiction Treatment In The US: Uneven Access, Waitlists, And High Costs
King C, Beetham T, Smith N, Englander H, Button D, Brown P, Hadland S, Bagley S, Wright O, Korthuis P, Cook R. Adolescent Residential Addiction Treatment In The US: Uneven Access, Waitlists, And High Costs. Health Affairs 2024, 43: 64-71. PMID: 38190597, PMCID: PMC11082498, DOI: 10.1377/hlthaff.2023.00777.Peer-Reviewed Original ResearchConceptsUse disordersRecent nonfatal overdoseOpioid use disorderResidential addiction treatment facilityResidential addiction treatment centerSelf-pay patientsSubstance use disordersDrug overdose deathsAddiction treatment facilitiesAddiction treatment centersResidential addiction treatmentNonfatal overdoseSixteen-year-old childrenTreatment optionsHalf of facilitiesMean costOverdose deathsTreatment centersResidential treatment facilitySubstance abuseAddiction treatment
2023
Treatments Used Among Adolescent Residential Addiction Treatment Facilities in the US, 2022
King C, Beetham T, Smith N, Englander H, Hadland S, Bagley S, Korthuis P. Treatments Used Among Adolescent Residential Addiction Treatment Facilities in the US, 2022. JAMA 2023, 329: 1983-1985. PMID: 37314282, PMCID: PMC10265296, DOI: 10.1001/jama.2023.6266.Peer-Reviewed Original Research
2022
Physician response to COVID-19-driven telehealth flexibility for opioid use disorder.
Beetham T, Fiellin DA, Busch SH. Physician response to COVID-19-driven telehealth flexibility for opioid use disorder. The American Journal Of Managed Care 2022, 28: 456-463. PMID: 36121359, DOI: 10.37765/ajmc.2022.89221.Peer-Reviewed Original ResearchConceptsOpioid use disorder treatmentCOVID-19 pandemicEarly COVID-19 eraOpioid use disorderUse disorder treatmentOUD treatmentTelehealth useUse disordersPhysician responsesTelehealth effectivenessDisorder treatmentTelehealth technologyPhysiciansTelehealthCOVID-19 eraTelehealth regulationsCOVID-19Administrative dataMost respondentsTreatmentRetrospective usePandemicSurvey participationPerceptions of effectivenessRespondents' use
2021
Admission Practices And Cost Of Care For Opioid Use Disorder At Residential Addiction Treatment Programs In The US
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Admission Practices And Cost Of Care For Opioid Use Disorder At Residential Addiction Treatment Programs In The US. Health Affairs 2021, 40: 317-325. PMID: 33523744, PMCID: PMC8638362, DOI: 10.1377/hlthaff.2020.00378.Peer-Reviewed Original ResearchConceptsOpioid use disorderUse disordersResidential addiction treatment programCost of careShort-term residential careAddiction treatment programsResidential programsClinical evaluationCare settingsRecruitment techniquesCostly treatmentTreatment programAddiction treatmentVulnerable populationsResidential careAudit surveyAdmissionOne-thirdCareDisordersTreatmentMost programsAdmission practicesProfit programsTreatment bed
2020
Therapies Offered at Residential Addiction Treatment Programs in the United States
Beetham T, Saloner B, Gaye M, Wakeman SE, Frank RG, Barnett ML. Therapies Offered at Residential Addiction Treatment Programs in the United States. JAMA 2020, 324: 804-806. PMID: 32840587, PMCID: PMC7448823, DOI: 10.1001/jama.2020.8969.Peer-Reviewed Original ResearchConceptsResidential addiction treatment programOpioid agonist treatmentResidential addiction treatment facilityOpioid use disorderAddiction treatment facilitiesAddiction treatment programsNonpharmacologic therapiesAgonist treatmentPatient callsUse disordersTreatment programCenter statusTherapyRandom sample
2019
Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study.
Beetham T, Saloner B, Wakeman SE, Gaye M, Barnett ML. Access to Office-Based Buprenorphine Treatment in Areas With High Rates of Opioid-Related Mortality: An Audit Study. Annals Of Internal Medicine 2019, 171: 1-9. PMID: 31158849, PMCID: PMC7164610, DOI: 10.7326/m18-3457.Peer-Reviewed Original ResearchConceptsBuprenorphine treatmentBuprenorphine prescribersBuprenorphine prescriptionsFirst visitHeroin useActive heroin useBuprenorphine-naloxone treatmentCurrent heroin useOpioid use disorderOpioid-related mortalityReal-world accessClinician typeBuprenorphine inductionPayer statusNew appointmentsHigh burdenBuprenorphine accessFirst appointmentMedicaid coverageUse disordersPatientsDrug abusePrescribersMedicaidNational Institute